Browse the record
Rehearse your PBAC submission against every public decision.
The record is free to explore; the dry-run is the work.
It also tracks what moved at the last meeting, what has been recommended and is still waiting for a listing, and what is on the agenda next.
4,271
PBAC decisions on record
$18.4B
PBS spend · 2024
14×
Spend growth since 2005
221.7M
Subsidised scripts · 2024
Latest decisions
| Drug | Therapy | Indication | Outcome | Decided |
|---|---|---|---|---|
| Adalimumab | Rheumatology | Moderate to severe ulcerative colitis, severe Crohn disease, sev… | Recommended · restricted | Mar 2026 |
| Adalimumab | Rheumatology | Treatment of multiple autoimmune conditions including severe Cro… | Recommended · restricted | Mar 2026 |
| Adrenaline (Epinephrine) | Immunology | Emergency treatment of acute severe allergic reactions in childr… | Recommended · restricted | Mar 2026 |
| Alectinib | Oncology | Adjuvant therapy for anaplastic lymphoma kinase (ALK)-positive n… | Recommended · restricted | Mar 2026 |
| Amivantamab | Oncology | Treatment of patients with epidermal growth factor receptor gene… | Recommended · restricted | Mar 2026 |
| Respiratory Syncytial Virus Vaccine, Recombinant, Pre-Fusion F Protein 3, Older Adult | Vaccines | Prevention of RSV-confirmed lower respiratory tract disease (LRT… | Recommended | Mar 2026 |
| Asciminib | Haematology | Addition of nurse practitioners as eligible prescribers for cont… | Recommended · restricted | Mar 2026 |
| Avacincaptad Pegol | Ophthalmology | Treatment of adult patients with geographic atrophy (GA) seconda… | Recommended · restricted | Mar 2026 |
| Canakinumab | Rare disease | Treatment of paediatric colchicine-resistant or intolerant famil… | Recommended · restricted | Mar 2026 |
| Cannabidiol | Neurology | Severe myoclonic epilepsy in infancy (Dravet syndrome) — treatme… | Recommended · restricted | Mar 2026 |
| Ciclosporin | Ophthalmology | Chronic severe dry eye disease with keratitis in adult patients … | Recommended · restricted | Mar 2026 |
| Dupilumab | Respiratory | Add-on maintenance treatment for adults with uncontrolled chroni… | Recommended · restricted | Mar 2026 |
| Durvalumab | Oncology | Perioperative treatment (neoadjuvant and adjuvant) of adult pati… | Recommended · restricted | Mar 2026 |
| Efgartigimod Alfa | Neurology | Treatment of adult patients with generalised myasthenia gravis (… | Recommended · restricted | Mar 2026 |
| Enzalutamide | Oncology | Treatment of non-metastatic hormone sensitive prostate cancer (m… | Recommended · restricted | Mar 2026 |
| Glycomacropeptide Formula With Long Chain Polyunsaturated Fatty Acids And Docosahexaenoic Acid And Low In Phenylalanine | Metabolic | Dietary management of phenylketonuria (PKU) in children from 3 y… | Recommended · restricted | Mar 2026 |
| Incobotulinumtoxina | Neurology | Moderate to severe spasticity of the lower limb in adults follow… | Recommended · restricted | Mar 2026 |
| Inotuzumab Ozogamicin | Haematology | Relapsed or refractory CD22-positive B-cell precursor acute lymp… | Noted | Mar 2026 |
| Lanreotide | Endocrinology | Treatment of acromegaly, functional carcinoid tumour, and non-fu… | Recommended | Mar 2026 |
| Loncastuximab Tesirine | Haematology | Treatment of adult patients with relapsed or refractory diffuse … | Not recommended | Mar 2026 |
| Mepolizumab | Respiratory | Add-on maintenance treatment for adults with uncontrolled chroni… | Recommended · restricted | Mar 2026 |
| Nemolizumab | Dermatology | Treatment of patients aged 12 years or older with chronic severe… | Recommended · restricted | Mar 2026 |
| Nivolumab | Oncology | Treatment of multiple advanced or metastatic cancers including m… | Not recommended | Mar 2026 |
| Obinutuzumab | Rheumatology | Treatment of adult patients with active class III or IV lupus ne… | Recommended · restricted | Mar 2026 |
| Odevixibat | Hepatology | Treatment of cholestatic pruritus in Alagille syndrome (ALGS) in… | Not recommended | Mar 2026 |
| Omalizumab | Respiratory | Treatment of uncontrolled severe asthma (USA), uncontrolled seve… | Recommended · restricted | Mar 2026 |
| Pegcetacoplan | Rare disease | Treatment of patients aged 12 years and older with complement 3 … | Not recommended | Mar 2026 |
| Pegvaliase | Metabolic | Treatment of patients aged 16 years and older with hyperphenylal… | Deferred | Mar 2026 |
| Retifanlimab | Oncology | Treatment of metastatic or recurrent, locally advanced Merkel ce… | Recommended · restricted | Mar 2026 |
| Retifanlimab | Oncology | Treatment of inoperable locally recurrent or metastatic squamous… | Recommended · restricted | Mar 2026 |
| Riluzole | Neurology | Treatment of amyotrophic lateral sclerosis (ALS), specifically i… | Noted | Mar 2026 |
| Risperidone | Mental health | Prevention of relapse of schizophrenia in adults following stabi… | Recommended · restricted | Mar 2026 |
| Romidepsin | Oncology | Treatment of adult patients with relapsed or refractory peripher… | Recommended · restricted | Mar 2026 |
| Ruxolitinib | Haematology | Addition of nurse practitioners as prescriber type for existing … | Recommended · restricted | Mar 2026 |
| Selpercatinib | Oncology | Advanced or metastatic medullary thyroid cancer (MTC) with RET v… | Recommended · restricted | Mar 2026 |
| Mrna-1273 | Vaccines | Prevention of coronavirus disease 2019 (COVID-19) caused by SARS… | Deferred | Mar 2026 |
| Tafamidis | Cardiovascular | Treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), spe… | Not recommended | Mar 2026 |
| Tafasitamab | Haematology | Relapsed or refractory follicular lymphoma in patients who have … | Recommended · restricted | Mar 2026 |
| Tarlatamab | Oncology | Treatment of adult patients with extensive-stage small cell lung… | Not recommended | Mar 2026 |
| Teclistamab | Oncology | Treatment of adult patients with relapsed or refractory multiple… | Recommended · restricted | Mar 2026 |
| Tildrakizumab | Dermatology | Continuing treatment of adults with severe chronic plaque psoria… | Recommended | Mar 2026 |
| Tirzepatide | Endocrinology | Treatment of adults with type 2 diabetes mellitus inadequately c… | Recommended · restricted | Mar 2026 |
| Tofersen | Neurology | Treatment of amyotrophic lateral sclerosis (ALS) associated with… | Recommended · restricted | Mar 2026 |
| Trastuzumab Deruxtecan | Oncology | Treatment of adult patients with hormone receptor positive (HR-p… | Not recommended | Mar 2026 |
| Upadacitinib | Gastroenterology | Complex refractory fistulising Crohn's disease with externally d… | Recommended · restricted | Mar 2026 |
| Ustekinumab | Dermatology | Treatment of adult patients with severe chronic plaque psoriasis… | Recommended | Mar 2026 |
| Vorasidenib | Oncology | Treatment of patients with WHO Grade 2 IDH-mutant astrocytoma or… | Recommended · restricted | Mar 2026 |
| Elranatamab | Haematology | Treatment of patients with relapsed or refractory multiple myelo… | — | Dec 2025 |
| Eplerenone | Cardiovascular | Chronic heart failure with left ventricular ejection fraction ≤4… | Recommended | Dec 2025 |
| Pembrolizumab | Oncology | Treatment of unresectable advanced and metastatic cancers, exclu… | Recommended | Dec 2025 |